Abstract:The RAS family of GTPases (HRAS, KRAS, NRAS) continue to present formidable challenges to the design of compounds that successfully and specifically target oncogenic RAS mutant populations in cancer. Although recent advances have led to the successful development of inhibitors specific to KRAS G12C (such as Sotorasib [Amgen] and Adagrasib [Mirati Therapeutics]), ongoing efforts seek to develop additional targeted inhibitors for oncogenic mutants of KRAS. Development of new KRAS targeted inhibitors requires the understanding of how a mutation impacts the accessibility of key residues within the protein, along with how each candidate compound interacts with populations of mutant and wild-type proteins. Proteomic analyses, typically comprising peptide-based methods to confirm compound localization or quantify binding kinetics, represent a key validation step for each phase of the inhibitor development process. However, these methods may not always provide a clear picture of how effectively the compound binds to the protein, how specific the compound is to the target residue, and how concentration or incubation time may impact these factors. To address this, we have developed a novel assay to evaluate target engagement in vitro employing top-down proteomics, which entails the analysis of intact protein molecules and their modified forms (proteoforms). By analyzing intact labeled or compound-treated recombinant KRAS4B proteins, we can directly visualize and precisely characterize each species within a sample. This method allows us to easily detect nonspecific binding, identify targeting of incorrect residues, and characterize unanticipated compound reaction products within a short LC-MS run, all facilitated by targeted MS2 fragmentation. Moreover, we have developed complementary methods for RAS proteoform quantitation, allowing for the evaluation of compound engagement to all proteoforms with greater accuracy than traditional peptide-based methods. We first performed a proof-of-concept experiment using a panel of KRAS4B G12D_C118S proteins with selected residues modified to cysteine to evaluate reactivity to maleimide-biotin over time. We then applied our optimized top-down assay to determine the engagement of targeted covalent inhibitors Sotorasib and Adagrasib with KRAS WT, G12C, or G13C in both the active (GppNHp) and inactive (GDPβS) states. Finally, we selected three compounds from a large-scale screen against a UCSF Small Molecule Discovery Center compound library and evaluated each for specificity to KRAS4B G13C over KRAS4B WT and KRAS4B G12C. Our results show the concentration dependence of target engagement and directly map compound binding location(s) without disrupting the protein's primary structure. Moreover, our ability to target discrete compound additions for top-down MS2 fragmentation provides context and order of preferential labeling of KRAS4B. Our hope is that this methodology may help accelerate the identification of new successful targeted inhibitors for KRAS and other RAS isoforms by the greater RAS community. Citation Format: Robert A. D'Ippolito, Caroline J. DeHart, Dana Rabara, Maria Abreu Blanco, Emily Alberico, Nitya Ramakrishnan, Stephanie Widmeyer, Simon Messing, David Turner, Michelle Arkin, Anna Maciag, Andrew Stephen, Dominic Esposito, Frank McCormick, Dwight V. Nissley. A top-down proteomic assay to evaluate KRAS4B-compound engagement [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl) nr A018.

Abstract 569: BIO-PROTAC: New treatment modality to treat undruggable KRAS mutants by application of cell penetrating scFv

Abstract 6061: Development of target cell-penetrating scFv conjugate degrader for the selective inhibition of mutant, resistant KRAS cancer

Abstract 6049: Cell-based PROTAC screening for cancer drug discovery

Targeted degradation of KRAS protein in non-small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles

Abstract 1127: Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide

Abstract 6050: Targeting KRAS G12D mutant tumors with the PROTAC degrader RP03707

Pan-KRAS destruction with a single PROTAC

Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent

Abstract 1216: Pan-RAS inhibition by a tumor-targeted biotherapeutic

Abstract 4111: Multi-peptide cancer vaccines targeting KRAS induce significant anti-tumor efficacy

Abstract 6717: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

Abstract LB352: Unraveling therapeutic potentials of mRNA-based cancer vaccine concurrently targeting heterogeneous KRAS mutant cancer

Abstract 1655: Targeting lipid metabolism disrupts KRAS oncogenesis in pancreatic cancer

Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers

Abstract B040: In silico drug design using KRASG12C as a theranostic target for pancreatic cancer

Abstract IA-08: Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer

Abstract A018: A top-down proteomic assay to evaluate KRAS4B-compound engagement

Abstract C096: Targeting Syndecan1 to overcome acquired resistant to KRAS inhibitor in gastrointestinal cancer

Abstract 5748: Inhibition of tumor growth using exosomes loaded with KRAS siRNA and surface-modified with tumor-targeted proapoptotic peptide

Abstract 519: A novel Skp1 inhibitor has potent preclinical efficacy against metastatic castration-resistant prostate cancer